Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Total Current Liabilities
All obligations due within one year.
Apogee Therapeutics, Inc.NASDAQ: APGE
Total Current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total current liabilities rises 18.9% from a year ago
Total current liabilities stood at $37.51M at the end of Q2 FY2026, up 18.9% from a year earlier and up 13.8% from the prior quarter. Over 3 fiscal years it compounded at +40.9% a year.
Context
- Total current liabilities amounted to 2.8% of total assets at the end of Q2 FY2026, down 2.0 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +18.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 27.91M USD
- Year-over-year change
- -2.3%
- 3-year CAGR
- +40.9%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 27.91M | -2.3% |
| FY2024 | 2024-12-31 | 28.56M | +38.9% |
| FY2023 | 2023-12-31 | 20.56M | +106.0% |
| FY2022 | 2022-12-31 | 9.98M | — |
Total Current Liabilities vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +18.9% is the 7th highest of 10, against a peer median of +29.3%.
- Total current liabilities amounts to 2.8% of total assets for APGE, versus a peer median of 10.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | Dec 2025 | CN¥1.64B CNY | +41.0% | +23.1% | 41.5% |
| Jun 2026 | $428.58M USD | +29.3% | +43.8% | 39.9% | |
| Mar 2026 | $325M USD | +11.4% | +13.7% | 25.1% | |
| Sep 2026 | $289.6M USD | -33.2% | +28.8% | 17.2% | |
| Jun 2026 | $86.87M USD | +117.5% | +85.8% | 10.5% | |
| Sep 2026 | $46.43M USD | +52.1% | +26.0% | 4.4% | |
| Sep 2026 | $45.3M USD | +18.2% | +22.6% | 3.8% | |
| Jun 2026 | $37.51M USD | +18.9% | +40.9% | 2.8% | |
| Mar 2026 | $36.57M USD | +51.1% | +3.8% | 5.7% | |
IRONDisc Medicine, Inc. | Sep 2026 | $34.36M USD | +28.5% | +17.5% | 4.9% |
| Peer median (excluding APGE) | — | +29.3% | +23.1% | 10.5% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.